# ENvue Medical, Inc. (FEED) — capital_raise/atm_program [pending]
Source: SEC API (secapi.ai) · situation sit_7114328abfc01662ed2e · retrieved 2026-08-14T08:07:30.873Z

## Overview
ENvue Medical, Inc. is an orthopedic, prosthetic and surgical appliances and supplies company.

ENvue Medical, Inc. entered into a Common Shares Purchase Agreement on August 12, 2026 with an institutional investor for a committed equity facility of up to $50.0 million. The Company has the right, at its sole discretion, to sell up to $50.0 million of common shares to the Investor from time to time during a 36-month investment period following commencement. The purchase price for shares will be 90% of the lowest volume weighted average price during the three trading days preceding each purchase date. The Company is required to use 40% of net proceeds to redeem outstanding Series X Preferred Stock until none remain outstanding, with the remainder used for working capital and general corporate purposes. The Company may terminate the agreement at any time after commencement with five trading days' notice at no cost or penalty.

## Terms
- Deal value: $50.0M · Consideration: stock

## Key dates
- Announced 2026-08-12

## Timeline
- 2026-08-12 · 8-K (0001493152-26-037254): 8-K - ENvue Medical, Inc. — *ENvue Medical, Inc. is an orthopedic, prosthetic and surgical appliances and supplies company.* ENvue Medical, Inc. entered into a Common Shares Purchase Agreement on August 12, 2026 with an institutional investor for a committed equity facility of up to $50.0 million. The Company has the right, at its sole discretion, to sell up to $50.0 million of common shares to the Investor from time to time during a 36-month investment period following commencement. The purchase price for shares will be 90% of the lowest volume weighted average price during the three trading days preceding each purchase date. The Company is required to use 40% of net proceeds to redeem outstanding Series X Preferred Stock until none remain outstanding, with the remainder used for working capital and general corporate purposes. The Company may terminate the agreement at any time after commencement with five trading days' notice at no cost or penalty.
  https://www.sec.gov/Archives/edgar/data/1326706/0001493152-26-037254.txt

## Citations
- 0001493152-26-037254 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000149315226037254